Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vanda Reports Strong Phase III Data For Sleep Disorder Candidate In Chronic Insomnia

This article was originally published in The Pink Sheet Daily

Executive Summary

VEC-162 also being tested in transient insomnia, circadian rhythm sleep disorders and mood disorders.
Advertisement

Related Content

“Not Approvable” Letter Leaves Vanda’s Schizophrenia Drug With Cloudy Future
“Not Approvable” Letter Leaves Vanda’s Schizophrenia Drug With Cloudy Future
Actelion Accepts Payoff Risk In GSK Deal For Phase III Insomnia Drug
Actelion Accepts Payoff Risk In GSK Deal For Phase III Insomnia Drug
Encouraging Phase III Data Reported For Vanda’s Schizophrenia Candidate
Vanda Moves Ahead With Development Of Iloperidone, VEC-162
Vanda Moves Ahead With Development Of Iloperidone, VEC-162

Topics

Advertisement
UsernamePublicRestriction

Register

PS067992

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel